Bone marrow mesenchymal stem/stromal cells from risk-stratified acute myeloid leukemia patients are anti-inflammatory in in vivo preclinical models of hematopoietic reconstitution and severe colitis.

We report that regardless of risk-group, bone-marrow mesenchymal stem/stromal cells from acute myeloid leukemia patients support, similar to those derived from healthy bone-marrow the survival, proliferation, differentiation and clonogenecity of CD34+ cells in vitro, and the in vivo immune deficient mice repopulating assays. Additionally, bone-marrow mesenchymal stem/stromal cells from acute myeloid leukemia patients were capable of reversing the inflammatory phenotype in preclinical models of acute severe colitis, showing a greater anti-inflammatory capacity compared to those derived from healthy bone marrow. Collectively, bone-marrow mesenchymal stem/stromal cells from acute myeloid leukemia patients retain the capacity to support healthy hematopoietic stem/progenitor cells and can suppress inflammation in vivo. PMID: 30237260 [PubMed - as supplied by publisher]
Source: Haematologica - Category: Hematology Authors: Tags: Haematologica Source Type: research